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Abstract
Background: Administration of recombinant luteinizing hormone (rLH) in controlled ovarian hyperstimulation may
benefit a subpopulation of patients. However, late follicular phase administration of high doses of rLH may also
reduce the size of the follicular cohort and promote monofollicular development.
Methods: To determine if rLH in late follicular development had a negative impact on follicular growth and
oocyte yield, IVF patients in our practice who received rFSH and rLH for the entire stimulation were retrospectively
compared with those that had the rLH discontinued at least two days prior to hCG trigger.
Results: The two groups had similar baseline characteristics before stimulation with respect to age, FSH level and
antral follicle count. However, the group which had the rLH discontinued at least two days prior to their hCG shot,
had a significantly higher number of oocytes retrieved, including a higher number of MII oocytes and number of
2PN embryos.
Conclusions: When using rLH for controlled ovarian hyperstimulation, administering it from the start of stimulation
and stopping it in the late follicular phase, at least two days prior to hCG trigger, may increase oocyte and embryo
yield.
Background
The precise benefit and use of recombinant luteinizing
hormone (rLH) is still debated. It is unclear which sub-
population benefits the most (e.g. poor responders,
extreme pituitary suppression, patients with anovula-
tion). Routine administration of rLH in antagonist cycles
may increase the peak serum E2 level but did not
increase the number of oocytes retrieved or increase
IVF pregnancy rates in one large randomized controlled
trial [1]. A recent case-control study however did show
a significant increase in implantation rates when rLH
was used with antagonist cycles [2]. Adding rLH after
day 6 of stimulation in a favorable prognosis population
does not seem to improve stimulation or pregnancy
rates either [3,4]. However, when an undesirable
response occurs after initial stimulation with FSH alone,
adding rLH rather than increasing the FSH dose may
increase the number of oocytes retrieved [5] and possi-
bly the pregnancy rate per transfer [6]. The optimal
dose and timing of rLH in controlled ovarian hypersti-
mulation is also unclear. One efficacy study showed an
increased pregnancy rate with 75 IU vs. 37.5 IU daily
(31% vs. 21% respectively) [7].
While the addition of rLH may increase response in
COH, very high doses of rLH (660 IU/day) in anovula-
tory women, who are at particular risk of ovarian hyper-
stimulation, may promote the growth of a single
dominant follicle [8], thereby reducing her risk for ovar-
ian hyperstimulation syndrome. It has therefore been
hypothesized that high dose rLH supplementation may
reduce the size of the developing follicular cohort. Late
follicular phase administration of rLH in doses of 225-
450 IU/day has also shown to minimize the number of
developing follicles in a smaller earlier study [9].
If poor responders potentially benefit from the addi-
tion of rLH but late follicular phase administration
reduces the total number of growing midsize follicles,
we hypothesized that stopping rLH in late follicular
development would increase the number of oocytes
obtained at retrieval. We performed a retrospective
review of IVF patients in our practice that were stimu-
lated with both rFSH and rLH to determine if stopping
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the rLH at least two days prior to hCG trigger increased
the number of oocytes retrieved.
Methods
Study design
Patients who received rLH in an IVF cycle at our clinic
between 2005-2007 were identified for chart review after
IRB approval. The two groups were assessed for age,
maximum FSH level, antral follicle count (AFC), type of
stimulation (Lupron microdose co-flare versus Lupron
down regulation protocol), whether cancellation
occurred for poor response, length of stimulation, daily
FSH and rLH dose, and peak estradiol (E2) and proges-
terone (P4) levels.
Patients on GnRH antagonists were excluded. At our
center, a microdose co-flare is preceded by luteal estra-
diol patches 0.1 mg applied every other day starting on
day 20 of the prior cycle. Lupron 20 units BID is then
started on day 2 of the cycle, at a concentration of 40
mcg/0.2 mL, and continued until day of hCG. The
down regulation protocol is started on day 21 of the
preceding cycle, initially at a dose of 20 units a day
(1 mg/0.2 mL) until down regulation is achieved. The
dose is then lowered to 10 units a day until day of hCG.
Patients are generally triggered with urinary hCG 10,000
units when the lead follicle is >20 mm, or two are
greater than 18 mm, with estradiol levels at approxi-
mately 200 pg/mL per follicle, preferably on day 10 of
stimulation.
Study groups
Both groups started stimulation with both rFSH and
rLH. The subjects were divided into two groups: (1)
those that had rLH stopped two or more days prior to
hCG (with only rFSH for late follicular development),
and (2) those that received rFSH and rLH until the day
of hCG trigger.
Outcome variables
Outcomes of interest included the rate of midsize folli-
cular growth (mm/day as measured by ultrasound),
number of oocytes retrieved (total and MII), number of
2PNs after fertilization, number of grade 1 embryos
available on day 3 of development, the number of
embryos available for cryopreservation on day 3, the
pregnancy rate as a measure of both positive beta hCG
per cycle start and clinical pregnancy by ultrasound per
cycle start. The vast majority of our cycles at our center
involve a cleavage stage embryo transfer on day 2 or 3,
therefore no blastocyst data is available.
Statistical analysis
The variables were assessed for distribution and consid-
ered reasonably normally distributed, therefore
continuous variables were compared with a two tailed
unpaired t-test, and proportions by Chi-square analysis
or in cases of very small numbers, a Fisher’s exact test.
Statistical analysis was performed with SAS v9.1. A p-
value of < 0.05 was considered statistically significant.
Results
56 patients were included in the study. Table 1 demon-
strates that the two groups were similar with respect to
age, day 3 FSH level, antral follicle count (AFC), type of
stimulation and cancellation rate. These characteristics
were also not significant among the patients who pro-
ceeded to egg retrieval. While the two groups were simi-
lar to each other, they were both in poor prognosis
categories: age = 37, FSH > 8 mIU/mL, and AFC < 12,
since the majority of good prognosis patients at our
clinic receive FSH alone. Consequently, nearly half of
the stimulations were with short protocol co-flares, with
a significant rate of cancellation (21-28%). The two
groups had similar lengths of stimulation, daily FSH
dose, and peak serum estradiol and progesterone levels.
However, the group which received rLH throughout the
entire stimulation (group 2), did have a small but signifi-
cantly higher daily rLH dose (119 IU/day vs. 97 IU/day,
p = 0.038).
Table 1 Subgroups baseline characteristics and outcomes





Age 37.0 37.5 0.7181
Max FSH (mIU/mL) 9.32 8.75 0.5451
AFC (2-10 mm) 10.98 10.50 0.4681
#/% co-flares 22(52.4%) 6(42.9%) 0.5372
#/% cancelled 12(28.6%) 3(21.4%) 0.7363
Patients who proceeded to egg
retrieval
(N = 30) (N = 11) p-val
Length of stimulation (days) 10.4 11.2 0.1661
Daily FSH dose (IU) 395 426 0.3811
Daily rLH dose (IU) 97 119 0.0381**
Peak E2 (pg/mL) 1892 1629 0.3221
Peak P4 (ng/mL) 1.21 0.88 0.0991
Outcomes Group 1 Group 2 p-val
Midsize follicular growth (mm/day) 0.96 0.78 0.4141
Oocytes retrieved 11.4 7.6 0.0411**
Number of MIIs 8.7 4.7 0.0191**
Number of 2PNs 6.8 3.5 0.0061**
Number of Grade 1 embryos 1.23 1.36 0.8171
Embryos for cryopreservation 1.1 0.5 0.4501
Positive bhCG/cycle start 27.5% 33.3% 0.7263
Clinical pregnancy/cycle start 25.0% 25.0% 1.0003
Group 1 (had rLH discontinued at least two days prior to hCG trigger) and
Group 2 (had rLH continued throughout stimulation)
1Unpaired two tailed t-test, 2Chi-sqare analysis, 3Fisher’s exact test
**Significant assuming a = 0.05
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Group 1 (rLH discontinued two or more days prior to
hCG trigger) had a significantly higher number of
retrieved oocytes (11.4 vs. 7.6, p = 0.041), metaphase II
oocytes (MIIs) (8.7 vs 4.7, p = 0.019) and pronuclear
stage embryos (2PNs) after one day of culture (6.8 vs
3.5, p = 0.006). Group 1 also had a greater number of
embryos for cryopreservation but this was not statisti-
cally significant. Clinical pregnancy rates were identical
in the two groups.
Discussion
Discontinuing rLH in late follicular development (at
least two days prior to hCG) may increase the number
of oocytes, MIIs and 2PNs in poor prognosis patients.
While this was demonstrated in this preliminary, small,
retrospective study, a larger prospective trial may deter-
mine whether this improves pregnancy rates in this sub-
population of IVF patients. It is likely that the use of
rLH in an unselected population confers no benefit in
live birth rates as demonstrated by a meta analysis
involving 701 patients [10]. This was also demonstrated
in a recent study of normal responders who received
rLH in the early follicular phase [11]. However, it is pos-
sible that baseline or stimulation serum LH levels may
help determine which group if any benefits from rLH
supplementation (and possibly when during the stimula-
tion). One study performed with oocyte donors found
rLH was only beneficial in donors with serum LH levels
< 1 IU/l at the start of stimulation [12].
Conclusions
When administering rLH at the beginning of controlled
ovarian hyperstimulation for a poor responder, stopping
the rLH and continuing FSH stimulation alone at least
two days prior to hCG trigger may increase the oocyte
yield at egg retrieval, possibly resulting in more MII
oocytes and 2PN embryos for the patient.
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